Achieving therapeutic goals in multiple sclerosis (MS) requires strict adherence to treatment schedules. This retrospective study analyzed persistence with, and to, fingolimod compared with injectable/infusible disease-modifying therapies (DMTs) patients MS.Patients the PharMetrics Plus™ US administrative claims database at least one prescription for, or administration of, fingolimod, glatiramer acetate (GA), interferon (IFN), natalizumab (index DMT) between October 1, 2010 September 30,...

Background Approximately one-third of patients with multiple sclerosis (MS) are unresponsive to, or intolerant of, interferon (IFN) therapy, prompting a switch to other disease-modifying therapies. Clinical outcomes switching therapy unknown. This retrospective study assessed differences in relapse rates among MS from IFN fingolimod glatiramer acetate (GA) real-world setting. Methods US administrative claims data the PharMetrics Plus™ database were used identify who switched GA between...

Background Approval of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies (mAbs), such as daratumumab, has reshaped treatment patterns in patients with multiple myeloma (MM) Japan. This retrospective study evaluated patient characteristics, patterns, trends MM using Medical Data Vision, the largest electronic health records database Japan anonymous inpatient outpatient information. Methods Patients aged ≥18 years, ≥2 an diagnostic disease code ≥1 record...

Abstract Background In 2023, two respiratory syncytial virus (RSV) vaccines became available in the United States (US) for adults aged ≥60 years and were recommended by Centers Disease Control Prevention’s Advisory Committee on Immunization Practices using shared clinical decision-making (i.e., requiring joint between healthcare professionals their patients). This study evaluated RSV vaccination uptake through February 2024, overall specific risk factors severe disease.Figure 1.Age-specific...

Abstract Background In January 2022, ACIP recommended 2 doses of recombinant zoster vaccine (RZV) for herpes (HZ) prevention in adults ≥ 19 years who are or will be immunodeficient immunosuppressed because disease therapy. While this decision served to address an unmet medical need, its impact on vaccination is not fully understood as RZV uptake and series completion estimates among immunocompromised (IC) lacking.Figure 1.RZV Uptake (>1 dose) by Patient Age Autoimmune Disease,...

While the incidence of pertussis has increased in adolescents and adults recent years U.S., little is known about economic burden older adults. This study provides evidence direct medical charges associated with episodes care (PEOCs) aged 50 U.S. PEOCs were divided into periods before after initial diagnosis was made (i.e., index date) to capture any conditions immediately preceding that may have represented misdiagnoses subsequent sequelae. Data extracted from IMS's recently acquired SDI...

To provide updated estimates of the clinical and economic burden in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) by disease severity United States to estimate incremental costs associated progression.Retrospective cohort study.Patients 1 more International Classification Diseases, 10th Revision, Clinical Modification, diagnoses for OAG OHT who are 40 years age older.Patients were identified from IQVIA's PharMetrics Plus database during index period (October 1, 2015,...

Negligible real-world evidence exists for later line treatment of multiple myeloma (MM) to assist decisions or reimbursement models, such as episode-based payments.To describe the patterns and clinical/economic outcomes when pomalidomide carfilzomib is used relapsed/refractory MM.A U.S. claims database was identify MM patients with an initial claim (index date) between February 1, 2013, 28, 2015, which assumed be relapse therapy. Treatment regimens were defined all chemotherapy observed...

Disease-modifying therapies, such as fingolimod, interferon (IFN) and glatiramer acetate (GA), have differing effects on relapse rates in patients with multiple sclerosis (MS), but little is known about the real-world differences these treatments. This retrospective study assessed active MS initiating IFN or GA therapy a setting.

In the United States, incidence of acute myeloid leukemia (AML) has steadily increased over last decade; in 2019, it was estimated that AML would affect 21,450 new patients and lead to 10,920 deaths. Detailed real-world cost estimates comparisons key treatment episodes, such as high-intensity chemotherapy (HIC), low-intensity (LIC), hematopoietic stem cell transplantation (HSCT), relapsed/refractory (R/R), are scarce commercially insured U.S.To examine health resource utilization (HRU),...

Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 the United States (US) for prevention of herpes adults aged 50 years and older. The vaccine is administered two doses, with second dose administration recommended between six months after first dose. Examination uptake series completion important to ensure appropriate use, especially at time introduction. This report provides demographic characteristics patients receiving RZV September 2019, first- second-dose uptake, a...

Annual respiratory syncytial virus (RSV) outbreaks throughout the US exhibit variable patterns in onset, peak month of activity and duration season. RSVAlert, a surveillance system, collects characterizes RSV test data at national, regional, state local levels.RSV from 296 to 666 laboratories 50 states, District Columbia Puerto Rico (as 2010) were collected during 2007-2008 2011-2012 seasons. Data early August/September following each Participating provided total number types tests performed...

BACKGROUND: New treatment alternatives have revolutionized the management of nAMD. However, there is limited evidence on clinical and economic burden nAMD in commercially insured US patients. OBJECTIVES: To examine patients with by disease status patient population to identify drivers nAMD-related costs. METHODS: Patients at least 1 International Classification Diseases, 10th Revision Clinical Modification (ICD-10-CM) diagnosis for were identified from IQVIA PharMetrics Plus database between...

This retrospective study estimated healthcare resource use (HRU), symptoms and toxicities (SxTox), costs in relapsed/refractory (R/R) patients with acute myeloid leukemia (AML), stratified by hematopoietic stem cell transplantation (HSCT) status. Claims data were used to identify adult AML diagnoses from 1 January 2008 31 March 2016 the USA. Patients considered R/R if they had an relapse ICD-9 code (205.02) or a line of therapy consistent disease. The final sample (N = 707) included 476 231...

The introduction of pertussis vaccination in the United States (US) 1940s has greatly reduced its burden. However, incidence is difficult to quantify, as many cases are not laboratory-confirmed or reported, particularly adults. This study estimated a commercially insured US population aged <50 years. Data were extracted from IMS' PharMetrics Plus claims database for patients with diagnosis cough illness using International Classification Diseases (ICD-9) codes, commercial outpatient...

Precis: Incremental addition of intraocular pressure–lowering topical drops is associated with shorter-lasting benefit and higher health-related costs each additional agent, suggesting a need for new treatment options to improve disease control reduce burden. Purpose: The purpose this study was evaluate intensification as driver clinical economic burden in patients receiving glaucoma medications open-angle glaucoma/ocular hypertension. Methods: This retrospective analysis administrative...

Antigen detection tests have been the most common diagnostic assay used to detect and diagnose respiratory syncytial virus (RSV). The utility increased sensitivity of polymerase chain reaction (PCR) reported; however, their use in US hospital laboratories is not well characterized. To describe changes RSV test types by hospital-affiliated laboratories, focusing on PCR testing prevalence. Data were collected from 480 666 each season (2007–2008 through 2010–2011) across 50 states, District...

Aims To evaluate the prevalence and risk factors of migraine progression to assess incremental burden on healthcare systems.Materials methods Adult patients were required have a diagnosis in IQVIA's US adjudicated claims database between 1 January 2012 30 June 2016, continuous enrollment ≥12 months before after index date (i.e. first observed diagnosis), ≥1 additional claim during 12-month post-index period. A previously-developed algorithm identified with prevention-eligible episodic (EM)....

<h2>Abstract</h2><h3>Background/Objectives</h3> Vaccination against herpes zoster (HZ) is an effective strategy in protecting the population consequences of varicella virus reactivation. Optimal immunogenicity with recombinant vaccine (RZV) relies on completion 2-dose series within 2-6 months from first dose. The objectives this study were to estimate RZV rates and adherence recommended administration schedule general United States aged at least 50 years evaluate factors influencing rates....

While the efficacy of dupilumab for treatment adults with moderate-to-severe atopic dermatitis (AD) has been demonstrated in several clinical trials, patients such trials may not necessarily reflect real-world practice setting. This study evaluated effectiveness AD based on physician global assessment, percent body surface area affected, and patient-reported itch. From Modernizing Medicine's Electronic Medical Assistant dermatology-specific electronic medical records, (≥ 18 years) were...

Background In the United States, few studies have evaluated geographic variation of severe asthma at subnational level. Objective To assess state-level in prevalence and characteristics persistent States. Methods Patients ≥12 years old with were identified using nationally representative data from IQVIA open-source Medical/Pharmacy Claims PharMetrics Plus® databases (January 2019–December 2020). The index date was defined as patient's earliest qualifying for a diagnosis. Baseline measured...

Objective: Compare relapse rates among patients with multiple sclerosis (MS) who switch from interferon (IFN) to fingolimod or glatiramer acetate (GA). Background: The clinical outcomes of switching disease-modifying therapy (DMT) in are unknown. Methods: US administrative claims data the PharMetrics Plus™ Database were analyzed retrospectively identify GA between 10/01/2010 and 09/30/2011. study included switched within 90 days discontinuing IFN had an MS diagnosis code 360 switching....

Several risk factors for severe hypoglycaemia (SH) are associated with insulin-treated diabetes. This study explored potential in adults type 2 diabetes mellitus (T2DM).In this case-control study, T2DM initiating insulin were identified the IQVIA PharMetrics® Plus database. The index date was of first SH event (cases). Using incidence-density sampling, controls selected from those who had been exposed 'at risk' same amount time as each case. After exact-matching on well-established factors,...

Abstract Background Real-world evidence for brigatinib, a next-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) used in ALK-rearranged non-small cell lung cancer, is scarce. This retrospective study evaluated real-world brigatinib utilization the US post other ALK-TKIs. Materials and Methods Adults with ≥1 claim (index date) between 1 April 2017 30 September 2020 IQVIA longitudinal pharmacy claims database were followed until dose reduction, discontinuation, or end...

Information on the long-term treatment satisfaction with secukinumab for patients plaque psoriasis in real-world settings is limited. The objective of this study was to describe who initiated using data from an electronic medical records-based dermatology database. Patients aged ≥ 18 years Modernizing Medicine Data Services' affiliate's database received 3/1/2018-1/21/2020 were included. Satisfaction treatment's effectiveness clearing skin evaluated a 5-point Likert scale during 12-month...